New hypoglycemic agents and the kidney: what do the major trials tell us? [version 1; referees: 2 approved]
As the burden of diabetic kidney disease continues to expand, new therapies to preserve renal function or prevent diabetic nephropathy are urgently needed. In the past decade, a number of new hypoglycemic classes have emerged, each with a unique profile of action and benefits. Here we review the imp...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
F1000 Research Ltd
2018-11-01
|
| Series: | F1000Research |
| Online Access: | https://f1000research.com/articles/7-1844/v1 |